Comprehensive Psychiatry
Volume 41, Issue 1 , Pages 4-12, January 2000

Comorbid personality impairment in body dysmorphic disorder

  • Lisa J. Cohen

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Lisa J. Cohen, Ph.D., Department of Psychiatry, 6 Karpas, Beth Israel Medical Center, Ist Ave & 16th St, New York, NY 10003.
    • Department of Psychiatry, Beth Israel Medical Center, New York,USA
    • New School for Social Research, New York, USA
    • Columbia University, New York; and Mount Sinai School of Medicine, New York, NY, USA
  • ,
  • Priscilla Kingston

      Affiliations

    • Department of Psychiatry, Beth Israel Medical Center, New York,USA
    • New School for Social Research, New York, USA
    • Columbia University, New York; and Mount Sinai School of Medicine, New York, NY, USA
  • ,
  • Andrew Bell

      Affiliations

    • Department of Psychiatry, Beth Israel Medical Center, New York,USA
    • New School for Social Research, New York, USA
    • Columbia University, New York; and Mount Sinai School of Medicine, New York, NY, USA
  • ,
  • Jee Kwon

      Affiliations

    • Department of Psychiatry, Beth Israel Medical Center, New York,USA
    • New School for Social Research, New York, USA
    • Columbia University, New York; and Mount Sinai School of Medicine, New York, NY, USA
  • ,
  • Bonnie Aronowitz

      Affiliations

    • Department of Psychiatry, Beth Israel Medical Center, New York,USA
    • New School for Social Research, New York, USA
    • Columbia University, New York; and Mount Sinai School of Medicine, New York, NY, USA
  • ,
  • Eric Hollander

      Affiliations

    • Department of Psychiatry, Beth Israel Medical Center, New York,USA
    • New School for Social Research, New York, USA
    • Columbia University, New York; and Mount Sinai School of Medicine, New York, NY, USA

Abstract 

Personality impairment was evaluated in 17 body dysmorphic disorder (BDD) patients undergoing a treatment study of clomipramine versus desipramine. Semistructured interviews were administered using both categorical (Structured Clinical Interview for DSM [SCID II]) and dimensional (Dimensional Assessment of Personality Impairment [DAPI]) methods. Personality measures were also correlated with a range of clinical variables (severity of BDD and depressive symptoms, age, duration of illness, and response to treatment). A secondary aim of the study was to provide preliminary validation for the DAPI. Consistent with previous studies, BDD patients showed considerable personality pathology. By SCID 11, patients met criteria for a mean of 2.53 personality disorder diagnoses; 87% of patients met criteria for at least 1 diagnosis and 53% for more than 1. Cluster C diagnoses were the most common. Mean scores for the DAPI were 2.63 (3 = mild impairment) to 6.41 (7 = severe impairment), averaging 5.26 (5 = moderate). With regard to the DAPI, the results provided preliminary evidence of good reliability and validity. Moreover, both personality measures were highly intercorrelated. Although SCID 11 diagnoses correlated with baseline depression (Hamilton Rating Scale for Depression [HRSD]) scores, there were few other significant correlations between personality and other clinical variables. Of note, however, treatment responders demonstrated less personality impairment than nonresponders. The finding that personality measures were highly intercorrelated but, on the whole, not well correlated with other clinical measures supports the distinct and dissociable nature of personality phenomena in BDD. Despite the small sample size, these results suggest that personality impairment appears to be significant factor in BDD and may even play a role in treatment response.

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by Food and Drug Administration Grant No. FDR-000941-01 (EH.).

PII: S0010-440X(00)90124-X

Comprehensive Psychiatry
Volume 41, Issue 1 , Pages 4-12, January 2000